Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04637243 · ClinicalTrials.gov registry record
Outcomes From Treatment Liver and Bile Duct Diseases
A clinical trial, sponsored by Methodist Health System.
- Active
- Registry status
- 126
- Enrollment target
NCT04637243: Active study, sponsored by Methodist Health System.
NCT04637243 is a clinical trial that is active but no longer recruiting, run by Methodist Health System. The registered enrollment target is 126 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04637243 is active but no longer recruiting, sponsored by Methodist Health System.
- ACTIVE NOT RECRUITING
- Registry status
- 126 participants
- Enrollment target
Study Summary
It is reported in the literature that the treatment of any liver and bile duct disease process, whether benign or malignant, continues to be a huge challenge. For example, patients with adenocarcinoma continue to be diagnosed at an advanced stage with medical and surgical options that are improving in terms of outcome measurements but with much more room for improvement. Our goal is to continue to review our treatment outcomes to further improve overall survival, overall symptom control, mortality and morbidity. The main aim of this study is to evaluate and compare the outcomes from our multiple treatments of benign or malignant liver and bile duct diseases.
Primary Outcome
Mortality
Interventions
- OTHER Treatment of Benign or Malignant Liver and Bile Duct Diseases
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2023-03-09 |
| Est. Completion | 2026-12-31 |
What the registry record for NCT04637243 still lists
NCT04637243 is an observational study that tracks outcomes without assigning an intervention. The registered 126 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Treatment of Benign or Malignant Liver and Bile Duct Diseases is the first listed.
NCT04637243 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04637243 about?
NCT04637243 is a clinical study titled "Outcomes From Treatment Liver and Bile Duct Diseases". It is reported in the literature that the treatment of any liver and bile duct disease process, whether benign or malignant, continues to be a huge challenge. For example, patients with adenocarcinoma continue to be diagnosed at an advanced stage with medical and surgical options that are improving ...
What is the current status of trial NCT04637243?
This trial is currently active not recruiting. The enrollment target is 126 participants. The study started on 2023-03-09. Estimated completion is 2026-12-31.
What interventions are being tested in trial NCT04637243?
The interventions under investigation include: Treatment of Benign or Malignant Liver and Bile Duct Diseases (OTHER).
Who is sponsoring clinical trial NCT04637243?
This trial is sponsored by Methodist Health System, which has 125 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01873131 · 126 participants · NA
A Clinical Trial of Pulsed-dye Laser Versus Timolol Topical Solution Versus Observation on the Growth of Hemangioma in Newborn
- NCT02621645 · 126 participants · Phase 4
TRAP Intervention STudy: Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence
- NCT03838107 · 126 participants
Markers of Trajectory in Pediatric CRPS
- NCT03906422 · 126 participants · NA
Comparison of Patient-reported Pain After Initial Archwire Placement
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI